Drugs Containing Excipient (Inactive Ingredient) CALCIUM ALGINATE

« Back to Dashboard

Generic drugs containing CALCIUM ALGINATE excipient

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	mefloquine hydrochloride	0054-0025	CALCIUM ALGINATE
Actavis Pharma Inc	metaxalone	0591-2341	CALCIUM ALGINATE
medsource pharmaceuticals	metaxalone	45865-985	CALCIUM ALGINATE
A-S Medication Solutions	metaxalone	50090-3174	CALCIUM ALGINATE
Unit Dose Services	metaxalone	50436-0449	CALCIUM ALGINATE

Calcium Alginate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 28, 2026

Calcium alginate is a specialty, seaweed-derived excipient and medical-material component used for gel formation, controlled release, wound care, dental products, and encapsulation. Its commercial value is driven less by bulk volume than by grade qualification, viscosity control, calcium-release behavior, microbiological quality, and regulatory documentation. Public companies generally do not report calcium alginate revenue separately, so a standalone market size or company-level revenue forecast cannot be established from audited disclosures.

The market outlook is structurally positive in high-value applications, especially wound dressings, tissue engineering, oral controlled-release systems, and bioprinting. Growth is constrained by substitution from sodium alginate, pectin, carrageenan, cellulose derivatives, synthetic polymers, and newer hydrogel systems.

What is calcium alginate and how is it used in pharmaceutical products?

Calcium alginate is the calcium salt of alginic acid, a polysaccharide extracted primarily from brown seaweed. Its principal technical function is ionic gelation. Calcium ions cross-link alginate chains, producing a hydrophilic gel that can absorb fluid and control diffusion.

Attribute	Commercial relevance
Chemical origin	Brown seaweed-derived alginate
Primary mechanism	Calcium-mediated ionic cross-linking
Key properties	Gel formation, water absorption, viscosity, film formation
Main pharmaceutical uses	Wound dressings, drug delivery, encapsulation, matrix systems
Main non-pharmaceutical uses	Food stabilization, dental materials, tissue engineering
Critical specifications	Viscosity, guluronic-to-mannuronic acid ratio, calcium content, ash, microbial limits
Main substitutes	Sodium alginate, pectin, carrageenan, cellulose ethers, carbomers, synthetic hydrogels

Calcium alginate is particularly useful where a formulation requires a pre-cross-linked alginate matrix or calcium release. Sodium alginate is more commonly used as the processable starting material because it dissolves more readily and can be converted into calcium alginate in situ.

What formulations are protected by calcium alginate?

Calcium alginate is used in several formulation categories, but its commercial importance differs by dosage form.

Wound dressings

Wound dressings are the most established high-volume medical application. Calcium alginate fibers absorb wound exudate and convert into a gel. The gel can help maintain a moist wound environment and support atraumatic dressing removal.

Commercial products commonly combine calcium alginate with sodium alginate, carboxymethylcellulose, or antimicrobial components such as silver. These products are generally regulated as medical devices rather than pharmaceutical products, depending on jurisdiction and product claims.

Oral controlled-release formulations

Calcium alginate can function as a matrix former, bead-forming polymer, or release-rate modifier. Active ingredients may be encapsulated in alginate beads through external or internal gelation. Applications include systems designed to delay release, protect unstable ingredients, or modify gastrointestinal residence time.

The main development risks are batch-to-batch variation, incomplete drug loading, premature disintegration, and sensitivity to ionic strength and pH.

Multiparticulate and encapsulation systems

Calcium alginate beads can be manufactured through extrusion, atomization, prilling, or dropping an alginate solution into a calcium chloride bath. These approaches are used in research and selected commercial formulations for oral, probiotic, nutraceutical, and biologic delivery.

Injectable and tissue-engineering systems

Calcium alginate hydrogels are used extensively in research involving cell encapsulation, regenerative medicine, and localized delivery. Pharmaceutical commercialization is more difficult because injectable products require tight control of endotoxin, residual impurities, sterilization, extractables, mechanical properties, and immunological response.

How large is the calcium alginate pharmaceutical excipient market?

No authoritative public source reports a standalone global revenue figure for pharmaceutical-grade calcium alginate. Public market reports usually aggregate calcium alginate with broader categories such as alginates, hydrocolloids, biopolymers, wound-care materials, or excipients.

The commercial market is best analyzed as a layered value chain:

Market layer	Revenue visibility	Economic profile
Seaweed and alginate feedstock	Publicly reported only at broad company or segment level	Commodity to specialty
Industrial sodium alginate	Sometimes reported by product family	Moderate margin
Pharmaceutical-grade alginate	Rarely reported separately	Higher margin
Calcium alginate excipient	Usually not separately disclosed	Specialty margin
Finished wound-care products	Reported by some medical-device companies	Highest product-level value capture
Drug-delivery platforms	Often project-based or undisclosed	High technical value, low current volume

Revenue is concentrated downstream. A kilogram of qualified calcium alginate generally has greater economic value than an equivalent quantity of industrial alginate because pharmaceutical customers pay for documentation, testing, traceability, consistency, and change-control support.

What is driving demand for calcium alginate?

Demand is supported by five commercial factors.

First, wound-care demand remains linked to chronic wounds, surgery, burns, pressure injuries, and diabetes-related complications. Calcium alginate dressings have an established clinical role where exudate management is required.

Second, pharmaceutical developers continue to evaluate natural polymers for controlled delivery and encapsulation. Alginate is biodegradable, relatively accessible, and compatible with aqueous processing.

Third, companies are developing plant-based and marine-derived excipient platforms to reduce reliance on petrochemical polymers. This does not guarantee substitution, because natural polymers introduce greater biological and compositional variability.

Fourth, alginate hydrogels are used in advanced therapy research, including cell encapsulation and regenerative medicine. These applications may expand demand for high-purity and low-endotoxin grades.

Fifth, regulatory familiarity supports adoption. Alginates have long histories in food, medical-device, dental, and pharmaceutical applications, although each finished product still requires route-specific qualification.

What limits the financial trajectory of calcium alginate?

The primary constraints are technical rather than demand-related.

Raw-material variability is a major issue. Alginate performance depends on seaweed species, geographic origin, harvesting conditions, extraction method, molecular weight, and guluronic-to-mannuronic acid ratio. These variables affect gel strength, viscosity, swelling, and release behavior.

Supply is exposed to marine-weather conditions, harvesting controls, environmental regulation, and geographic concentration. A manufacturer that changes seaweed source or processing conditions may trigger customer requalification.

Calcium alginate also faces substitution. Sodium alginate is often cheaper and easier to process. Pectin and gellan gum can deliver comparable gelation behavior in selected systems. Hydroxypropyl methylcellulose, ethylcellulose, carbomers, polyvinyl alcohol, and synthetic biodegradable polymers compete in controlled-release applications.

Sterilization can reduce product performance. Heat, radiation, and chemical sterilants may alter molecular weight or gel properties. This is a significant barrier for injectable and implantable applications.

What is the FDA regulatory status of calcium alginate?

Calcium alginate is not an active pharmaceutical ingredient and does not receive an independent FDA drug approval. Its regulatory status depends on its function, route, grade, and use in a finished product.

The FDA Inactive Ingredient Database is the principal public reference for excipients that have appeared in approved drug products. Database status must be evaluated by route and dosage form rather than by chemical name alone. Presence in the database does not constitute blanket approval for every concentration or application (U.S. Food and Drug Administration, n.d.-a).

Calcium alginate also has food-related regulatory history. U.S. food regulations identify calcium alginate as a permitted direct food substance under specified conditions of use, but food status does not automatically establish pharmaceutical acceptability (U.S. Food and Drug Administration, n.d.-b).

For pharmaceutical development, sponsors must establish:

• Identity and chemical characterization
• Molecular-weight or viscosity profile
• Calcium content and degree of cross-linking
• Residual heavy metals and inorganic impurities
• Microbial limits and endotoxin, where relevant
• Bioburden and sterilization compatibility
• Extractables and leachables for packaged systems
• Supplier qualification and change-control procedures

The European Medicines Agency guideline on excipients in the dossier emphasizes quality, safety, function, and route-specific justification for excipients used in medicinal products (European Medicines Agency, 2018).

What patents protect calcium alginate formulations?

Calcium alginate itself is an old, widely known material. Basic composition patents are unlikely to provide broad, current exclusivity over the compound. Commercial protection generally resides in the finished formulation, manufacturing process, device architecture, or use.

Protection category	Typical claim scope	Commercial relevance
Polymer composition	Molecular weight, calcium content, viscosity, purity	Moderate
Cross-linking process	Calcium source, concentration, timing, drying method	Moderate to high
Drug-loaded beads	Active ingredient, particle size, release profile	High if narrowly validated
Wound dressing structure	Fiber blend, absorbency, antimicrobial layer	High for branded devices
Injectable hydrogel	Sterility, mechanical properties, cell or drug payload	Potentially high
Manufacturing controls	Continuous gelation, particle formation, drying	Moderate
Method of use	Wound treatment, localized delivery, controlled release	Usually narrow and jurisdiction-specific

Patent rights are normally held by finished-product companies, device manufacturers, universities, or drug-delivery developers rather than by the excipient supplier alone. Patent searches must use multiple terms, including “calcium alginate,” “alginate hydrogel,” “alginate bead,” “alginate microsphere,” “alginate dressing,” and “ionic crosslinking.”

What is the Orange Book status of calcium alginate?

Calcium alginate has no standalone Orange Book listing because it is an excipient, not an approved active drug product. The Orange Book lists approved drug products and patent or exclusivity information associated with those products. It does not create an independent exclusivity right for an excipient.

Paragraph IV litigation also does not apply to calcium alginate as a raw material. A Paragraph IV certification may arise when a generic drug containing calcium alginate challenges patents listed for the finished drug, but the dispute would concern the drug product's listed patents, not calcium alginate ownership.

When does calcium alginate lose exclusivity?

Calcium alginate does not have a single market-wide patent expiration date. There is no unitary exclusivity period covering all calcium alginate grades, formulations, or uses.

Exclusivity depends on the relevant finished product:

• A basic calcium alginate composition may be unprotected or covered only by expired patents.
• A branded wound dressing may rely on formulation, device, or manufacturing patents with different expiration dates.
• A drug-delivery product may have method-of-use, formulation, or process patents.
• A supplier's proprietary grade may be protected primarily by trade secrets, specifications, know-how, and customer qualification rather than by patents.

This structure makes regulatory qualification more important than patent exclusivity in many excipient transactions.

Which companies participate in the calcium alginate supply chain?

The market includes seaweed harvesters, alginate manufacturers, specialty excipient suppliers, medical-device companies, and contract formulators. Public disclosures often group alginate within larger ingredient or biomaterials portfolios.

Relevant supplier and industry categories include:

• Specialty alginate producers
• Pharmaceutical excipient distributors
• Wound-dressing manufacturers
• Dental-material suppliers
• Contract development and manufacturing organizations
• Universities and biotechnology companies developing alginate hydrogels

Examples of established alginate industry participants include KIMICA, International Flavors & Fragrances through its alginate-related operations, and other regional alginate producers. Product availability, grade designation, and regulatory documentation vary by jurisdiction and must be verified against the supplier's current technical file.

How does calcium alginate compare with sodium alginate?

Factor	Calcium alginate	Sodium alginate
Water behavior	Forms or maintains calcium-linked gel	More readily hydrates and dissolves
Processing flexibility	Lower in some solution processes	Higher
Gel strength	Generally higher after cross-linking	Requires calcium or another cross-linking mechanism
Common pharmaceutical role	Matrix, bead, dressing, hydrogel	Binder, thickener, gel precursor
Formulation cost	Usually higher after processing	Often lower
Regulatory familiarity	Established but use-specific	Broad and well established
Main commercial advantage	Preformed or controllable gel structure	Ease of formulation and processing

For oral drug delivery, sodium alginate is often the starting material and calcium alginate is the final cross-linked matrix. For wound care, calcium alginate fiber is more directly relevant.

What generic entry risks exist for calcium alginate products?

Generic entry risk is low for the excipient itself because calcium alginate is widely available and generally not protected as a molecule. Risk is higher for finished products with:

• Narrow release specifications
• Difficult-to-reproduce bead size
• Complex cross-linking conditions
• Device-drug combination status
• Proprietary fiber architecture
• Antimicrobial incorporation
• Clinical performance tied to material structure
• Supplier-specific regulatory documentation

The principal barrier is often reproducibility rather than patent enforcement. A competing manufacturer may obtain the same chemical ingredient but fail to match gel strength, absorption, release rate, sterility, or clinical handling characteristics.

What licensing deals affect calcium alginate?

Licensing activity is more common around delivery platforms, biomaterials, wound-care products, and regenerative-medicine technologies than around bulk calcium alginate supply. Public companies rarely disclose calcium-alginate-specific royalty streams.

The most commercially relevant deal structures are:

• Exclusive rights to a drug-loaded alginate delivery platform
• University licensing of alginate hydrogel technology
• Contract manufacturing agreements for wound dressings
• Long-term supply agreements tied to a qualified grade
• Co-development arrangements for injectable or implantable systems
• Technology licenses covering bead formation or continuous gelation

Supply agreements can create practical switching costs even when patent protection is weak. A sponsor may need to repeat stability, extractables, biocompatibility, or clinical comparability work after changing suppliers.

What is the financial outlook for calcium alginate?

The financial trajectory is likely to separate into three segments.

Segment	Outlook	Margin profile
Industrial calcium alginate	Mature, volume-sensitive	Low to moderate
Pharmaceutical-grade excipient	Steady growth, qualification-driven	Moderate to high
Advanced hydrogel and delivery applications	Higher growth potential, uncertain adoption	High but development-dependent

Near-term revenue growth should remain strongest in wound-care materials and specialty grades. Drug-delivery demand can grow faster, but it is less predictable because many products remain in development or are produced at limited scale.

The best-positioned suppliers will have secure seaweed sourcing, multiple geographic production sites, validated pharmaceutical grades, low-bioburden options, technical support, and documented change-control systems. Suppliers dependent on one seaweed source or a single regional manufacturing site face greater supply and pricing risk.

Key Takeaways

• Calcium alginate is a specialty marine-derived excipient and biomaterial, not a standalone approved drug.
• Public financial reporting does not support a reliable calcium-alginate-only market size.
• Wound dressings are the most established commercial application.
• Oral controlled-release, encapsulation, injectable hydrogel, and regenerative-medicine uses provide higher-growth opportunities.
• The material has no single Orange Book listing and no standalone Paragraph IV exposure.
• Patent value usually resides in finished formulations, device structures, manufacturing processes, and methods of use.
• Regulatory qualification, supply continuity, and batch consistency are often more important than basic composition patents.
• Sodium alginate is the principal formulation substitute and process precursor.
• The market has moderate growth potential, with higher margins in pharmaceutical-grade and application-specific products.
• Revenue exposure is concentrated in specialty suppliers and finished-product manufacturers, not in a separately reported calcium-alginate business line.

FAQs

Is calcium alginate an active pharmaceutical ingredient?

No. Calcium alginate is generally used as an excipient, matrix former, gel-forming polymer, or medical-device material.

Can calcium alginate be used in oral tablets?

Yes. It can act as a matrix former or controlled-release component, although sodium alginate and cellulose derivatives are often easier to process.

Is calcium alginate FDA approved?

It does not receive standalone approval as an excipient. Its acceptability depends on the finished product, route, concentration, quality data, and FDA regulatory pathway.

Is calcium alginate suitable for injectable drugs?

It can be used in injectable hydrogel research and development, but injectable applications require substantially stricter controls for sterility, endotoxin, impurities, mechanical properties, and biocompatibility.

What is the main business risk in calcium alginate supply?

The main risks are raw-material variability, supplier changes, marine-resource disruption, inconsistent viscosity or gel strength, and the need for customer requalification after manufacturing changes.

References

European Medicines Agency. (2018). Guideline on the chemistry of active substances. https://www.ema.europa.eu/

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Electronic Code of Federal Regulations, Title 21, Part 184: Direct food substances affirmed as generally recognized as safe. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184

United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.